US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicines

84.90

0.0000

Volume:- -

Turnover:- -

Market Cap:6.79B

PE:-27.06

High:84.90

Open:84.90

Low:84.90

Close:84.90

Loading ...

Overview Company News Filings

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

Everest Medicines to Drop B Marker from Stock Short Name

MT Newswires Live

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

Everest Medicines Gains Approval for Listing Rule Changes

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Everest Medicines Announces Leadership Change and Clarifies ESOP Details

Kingworld Medicines Group Ltd. Adopts New Share Award Scheme

Novartis Commits $23 Billion to U.S. Expansion, Eyes Full Domestic Production of Key Medicines

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

Revolution Medicines Price Target Maintained With a $59.00/Share by Needham

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%

Simply Wall St.

3D Medicines Full Year 2024 Earnings: CN¥0.75 loss per share (vs CN¥2.30 loss in FY 2023)

Simply Wall St.

Praxis Precision Medicines to Participate in Upcoming April Conferences

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","market":"US","secType":"STK","nameCN":"Medicines","latestPrice":84.9,"timestamp":1578085200000,"preClose":84.9,"halted":3,"volume":0,"delay":0,"floatShares":74862655,"shares":79948329,"eps":-3.137449,"marketStatus":"Halted","change":0,"latestTime":"01-03 16:00:00 EST","open":84.9,"high":84.9,"low":84.9,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.137449,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":965707200000,"exchange":"NASDAQ","adjPreClose":84.9,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCO\",,,,,undefined,":{"symbol":"MDCO","floatShares":74862655,"roa":"-13.71%","roe":"553.30%","lyrEps":-1.673974,"shares":79948329,"dividePrice":0,"high":84.9,"amplitude":0,"preClose":84.9,"low":84.9,"week52Low":23.15,"pbRate":"178.02","week52High":84.98,"institutionHeld":1.2829,"latestPrice":84.9,"eps":-3.137449,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.137449,"open":84.9,"prevYearClose":84.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530542100","title":"BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2530542100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530542100?lang=en_us&edition=fundamental","pubTime":"2025-04-28 17:00","pubTimestamp":1745830800,"startTime":"0","endTime":"0","summary":"- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. - In as few as 3 months, the time to first event  durably separated relative to placebo- A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30- A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30. - Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK and Japan that all have a label specifying near-complete stabilization . - Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature1. - BridgeBio will receive royalties in a tiered structure beginning in the low-thirties percent on sales of Beyonttra in the UK. The approval in the UK is based on results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beyonttra-acoramidis-first-near-complete-090000954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CM","BK4094","BK4516","BK4585","LU2308191902.HKD","BK4528","MDCO","BBIO","BK4129","BK4137","BK4205","FL","BK4207","BK4505","BK4233","BK4588","ACM","UK","HCSG"],"gpt_icon":0},{"id":"2530905231","title":"Everest Medicines to Drop B Marker from Stock Short Name","url":"https://stock-news.laohu8.com/highlight/detail?id=2530905231","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530905231?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:20","pubTimestamp":1745572827,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) will cease to have the B marker attached to its stock short name from May 2, according to a Friday filing with the Hong Kong bourse.The biopharmaceutical company's new English stock short name will be EVEREST MED.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","01952","BK1161","BK1583","MDCO"],"gpt_icon":0},{"id":"2529832019","title":"Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2529832019","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529832019?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:00","pubTimestamp":1745316000,"startTime":"0","endTime":"0","summary":"New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region. Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion. “At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of our impact on people’s lives as we work to help treat or even cure devastating diseases,” said Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply at Regeneron. “We take our role seriously, and our decision to work with Fujifilm reflects our belief that they will meet our high standards and grow with us.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-announces-investment-manufacturing-industry-100000008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REGN","LU2106854487.HKD","MDCO","LU0823416689.USD","LU0058720904.USD","LU2237438978.USD","LU0882574055.USD","LU1974910355.USD","LU0289739699.SGD","LU0889565916.HKD","BK4585","LU0053666078.USD","LU2468319806.SGD","LU0320765992.SGD","LU2362541513.USD","LU2362540622.SGD","LU0109394709.USD","BK4139","LU2023250504.SGD","LU2089984988.USD","LU0114720955.EUR","BK4588","LU1917777945.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2529575773","title":"Everest Medicines Gains Approval for Listing Rule Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2529575773","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529575773?lang=en_us&edition=fundamental","pubTime":"2025-04-22 07:11","pubTimestamp":1745277068,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. ( ($HK:1952) ) has provided an update. Everest Medicines Limited announced that it has received approval from the Hong Kong ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-gains-approval-for-listing-rule-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-gains-approval-for-listing-rule-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2528799676","title":"EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799676","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799676?lang=en_us&edition=fundamental","pubTime":"2025-04-17 17:45","pubTimestamp":1744883135,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Incorporated  and Channel Therapeutics Corporation  on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc.  with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel.The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson.Under the merger agreement, Channel will acquire 100% of Pelthos’ issued and outstanding equity interests, change its name to Pelthos Therapeutics, and trade on the NYSE American exchange under the ticker PTHS.Upon completing the transaction, Scott Plesha, CEO of Pelthos, will become CEO of the combined company, and Frank Knuettel II, CEO of Channel Therapeutics, will become CFO. The transaction is expected to close in the summer of 2025.The combined company will initially focus on accelerating the commercialization of Pelthos’ Zelsuvmi  topical gel, 10.3%, for Molluscum contagiosum infections in adu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-ligand-subsidiary-pelthos-therapeutics-094535653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCO","BK4139","LENZ","CHRO","BK4007","LU1559883803.SGD","LGND","LU0566484027.USD"],"gpt_icon":0},{"id":"2527629431","title":"Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2527629431","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527629431?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:00","pubTimestamp":1744801200,"startTime":"0","endTime":"0","summary":"Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025. CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus. About CLN-978CLN-978 is a novel, differentiated and highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cellsin vitroandin vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size , CLN-978 contains two single-chain variable fragments, one b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-receives-approval-european-110000424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4110","CTA","ACR","CGEM","BK4139","MDCO"],"gpt_icon":0},{"id":"2527449856","title":"Everest Medicines Announces Leadership Change and Clarifies ESOP Details","url":"https://stock-news.laohu8.com/highlight/detail?id=2527449856","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527449856?lang=en_us&edition=fundamental","pubTime":"2025-04-15 22:37","pubTimestamp":1744727832,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Everest Medicines Ltd. ( ($HK:1952) ). Everest Medicines Ltd. has announced a change in its company secretary, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/everest-medicines-announces-leadership-change-and-clarifies-esop-details?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/everest-medicines-announces-leadership-change-and-clarifies-esop-details?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2527617851","title":"Kingworld Medicines Group Ltd. Adopts New Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2527617851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527617851?lang=en_us&edition=fundamental","pubTime":"2025-04-14 21:38","pubTimestamp":1744637889,"startTime":"0","endTime":"0","summary":"Kingworld Medicines Group Ltd. ( ($HK:1110) ) has provided an update. Kingworld Medicines Group Ltd. has announced the adoption of the 2025 Share A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kingworld-medicines-group-ltd-adopts-new-share-award-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kingworld-medicines-group-ltd-adopts-new-share-award-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2526647211","title":"Novartis Commits $23 Billion to U.S. Expansion, Eyes Full Domestic Production of Key Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2526647211","media":"GuruFocus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526647211?lang=en_us&edition=fundamental","pubTime":"2025-04-12 04:01","pubTimestamp":1744401677,"startTime":"0","endTime":"0","summary":"Novartis (NVS, Financials) is investing $23 billion over the next five years to expand its manufacturing and research footprint in the United States, aiming to make all key medicines for American pati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2774718/novartis-commits-23-billion-to-us-expansion-eyes-full-domestic-production-of-key-medicines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["MDCO"],"gpt_icon":0},{"id":"2526659031","title":"Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2526659031","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526659031?lang=en_us&edition=fundamental","pubTime":"2025-04-11 17:30","pubTimestamp":1744363800,"startTime":"0","endTime":"0","summary":"BOSTON, April 11, 2025----Vertex Pharmaceuticals Incorporated  today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award \"for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.\" Negulescu shares the award with Michael J. Welsh, M.D., University of Iowa.\"I am honored and humbled by this award that recognizes not only me, but also the dedication, creativity and scientific excellence of the thousands of people across Vertex, and in the CF community, who have been steadfast in their commitment to bringing these medicines to people with cystic fibrosis around the world,\" said Negulescu.Cystic fibrosis  is a rare, life-shortening genetic disease affecting more than 94,000 people globally. CF is a progressive, multi-organ disea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-researcher-paul-negulescu-ph-093000494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","IE0009355771.USD","IE0002141913.USD","LU1430594728.SGD","LU2324357040.USD","SG9999001176.SGD","LU2362541273.HKD","MDCO","LU1585245621.USD","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD","LU1815336091.USD","VTNR","IE00BJT1NW94.SGD","BK4588","LU0079474960.USD","LU0234570918.USD","IE00B19Z9P08.USD","LU0058720904.USD","BK4532","LU0256863811.USD","LU0823416689.USD","LU0889565916.HKD","LU2362541513.USD","BK4139","LU1093756325.SGD","VRTX","LU1093756168.USD","BK4585","LU2362540622.SGD","LU1069344957.HKD","IE0002270589.USD","LU2462157665.USD","LU1559883803.SGD","LU0417517546.SGD","VERX","SG9999013999.USD","IE00BJJMRZ35.SGD","BK4533","LU1035775433.USD","CF","LU0289739699.SGD","LU0757428866.USD","LU0320765992.SGD","BK4093","LU2456880835.USD","IE00BFTCPJ56.SGD","SG9999001176.USD","LU0061475181.USD"],"gpt_icon":0},{"id":"2526356596","title":"Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356596","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356596?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:17","pubTimestamp":1744193820,"startTime":"0","endTime":"0","summary":"Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.-- Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were all down 5% or more in European midday trade.-- Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, respectively.-- In U.S. premarket trading, Eli Lilly, Merck and Pfizer all fell at least 1%.The drug sector was spared from Trump's sweeping tariff plan that kicked in today, but the president's remarks at a Tuesday dinner with House Republicans suggested levies could come very shortly.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU2462157665.USD","LU0234572021.USD","IE0002270589.USD","IE00B2B36J28.USD","BK4568","GSK","IE00BLSP4239.USD","LU2456880835.USD","SG9999013999.USD","IE00BJT1NW94.SGD","LU0058720904.USD","LU0321505868.SGD","LU1066053197.SGD","LU0070302665.USD","LU0225284248.USD","IE00BFXG1179.USD","BK4533","LU1023059063.AUD","AZN","BK4588","BK4007","NVS","IE0009355771.USD","LU0208291251.USD","BK4532","IE00B19Z3B42.SGD","LU1894683264.USD","LU1894683348.USD","LU2236285917.USD","SNY","BK4599","LU0289739699.SGD","LU1829250122.USD","IE00B4R5TH58.HKD","LU0170899867.USD","LU0225771236.USD","SG9999001176.USD","MDCO","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","LU0889565916.HKD","03165","RHHBY","LU2417539215.USD","SG9999002232.USD","GSK.UK","SG9999003800.SGD","SG9999011175.SGD"],"gpt_icon":1},{"id":"2526133062","title":"Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2526133062","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526133062?lang=en_us&edition=fundamental","pubTime":"2025-04-09 17:24","pubTimestamp":1744190640,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks took a hit after U.S. President Trump said tariffs on pharma imports will be unveiled very shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil globally.In European morning trade, the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--was down 4.5%, against a 2.7% fall for the broader Stoxx Europe 600. The falls mirrored a selloff among pharma stocks in Asia.Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were down 5% or more in morning trade. Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, while Australia's CSL shed 5%.The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his remarks at a Tuesday dinner with House Republicans suggested levies could come soon.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","LU0471298694.HKD","LU1551013342.USD","LU1093756168.USD","TAK","LU1989771016.USD","LU0289739699.SGD","LU0965509101.SGD","LU0417517546.SGD","LU0965508806.USD","LU0079474960.USD","SG9999017495.SGD","IE00BDGV0183.EUR","LU2264538146.SGD","LU1718418525.SGD","NVS","BK4007","LU1366192091.USD","BK4559","ABBV","SG9999002224.SGD","03165","LLY","SGXZ99366536.SGD","IE0009355771.USD","DSNKY","RHHBY","SG9999014575.USD","LU0320765059.SGD","LU1732799900.SGD","SG9999014567.USD","SG9999015986.USD","GSK","LU1868836591.USD","LU2129689605.HKD","MRK","GSK.UK","LU0965509283.SGD","MDCO","BK4581","LU0061475181.USD","LU1934455277.USD","LU1988902786.USD","PFE","LU2133065610.SGD","LU1720051108.HKD","LU2237443978.SGD","LU1035773651.USD","LU0203201768.USD","SG9999013999.USD"],"gpt_icon":1},{"id":"2525880894","title":"Revolution Medicines Price Target Maintained With a $59.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2525880894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525880894?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:35","pubTimestamp":1744115700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:35 ET (12:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","MDCO"],"gpt_icon":0},{"id":"2525899331","title":"Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899331?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"BOSTON, April 08, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies  including:. The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs. The EMERALD study evaluating relutrigine for broader DEEs. The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE. To RSVP and attend the live event, you may click here. A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-hold-virtual-120000767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CNS","BK4139","MDCO","ASO","PRAX","BK4561","BK4200"],"gpt_icon":0},{"id":"2525852117","title":"The Price Is Right For Everest Medicines Limited (HKG:1952) Even After Diving 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525852117","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525852117?lang=en_us&edition=fundamental","pubTime":"2025-04-08 12:57","pubTimestamp":1744088241,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited ( HKG:1952 ) shareholders won't be pleased to see that the share price has had a very rough...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/the-price-is-right-for-everest-medicines-limited-hkg1952-eve","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01952","MDCO","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2525727429","title":"3D Medicines Full Year 2024 Earnings: CN¥0.75 loss per share (vs CN¥2.30 loss in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525727429","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525727429?lang=en_us&edition=fundamental","pubTime":"2025-04-06 09:57","pubTimestamp":1743904676,"startTime":"0","endTime":"0","summary":"3D Medicines ( HKG:1244 ) Full Year 2024 Results Key Financial Results Revenue: CN¥445.6m (down 30% from FY 2023). Net...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1244/3d-medicines-shares/news/3d-medicines-full-year-2024-earnings-cn075-loss-per-share-vs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDCO","CN","01244"],"gpt_icon":0},{"id":"2524128362","title":"Praxis Precision Medicines to Participate in Upcoming April Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524128362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524128362?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:00","pubTimestamp":1743714000,"startTime":"0","endTime":"0","summary":"BOSTON, April 03, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:. Praxis management will be presenting a corporate overview at the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on Monday, April 7, 2025 at 11:00a.m. EDT. A live webcast of the event will be available through this link.Praxis management will also be participating in the Piper Sandler Spring Biopharma Symposium, taking place at One Boston Place in Boston on Thursday, April 17, 2025.The Company will be available for one-on-one meetings during both events. Interested investors should contact their respective Needham and/or Piper Sandler representatives to request meetings.Replays of the webcasted events will","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-participate-upcoming-210000323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","PRAX","BK4139","BK4561","MDCO","BK4200","BK4135","ASO"],"gpt_icon":0},{"id":"2524421878","title":"Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System","url":"https://stock-news.laohu8.com/highlight/detail?id=2524421878","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524421878?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:01","pubTimestamp":1743710460,"startTime":"0","endTime":"0","summary":"Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets. Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales. Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, inclu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-announces-capsid-license-200100952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SGMO","BK4556","BK4139","MDCO","LENZ"],"gpt_icon":0},{"id":"2524725981","title":"Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa","url":"https://stock-news.laohu8.com/highlight/detail?id=2524725981","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524725981?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 03, 2025  -- Akebia Therapeutics, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the European Commission  to approve XOANACYL  for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease .“We congratulate our partner Averoa on a positive step toward securing EMA approval for XOANACYL, and we will continue to support their efforts to deliver a treatment for complications of kidney disease to patients in Europe,” said John P. Butler, Chief Executive Officer of Akebia.The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.About Akebia TherapeuticsAkebia Therapeutics, Inc.is a fully integrated biopharmaceutical company with the purpose to bet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/akebia-therapeutics-announces-positive-opinion-120000568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","EC","AKBA","BK4201","MDCO","BK4087","CHMP"],"gpt_icon":0},{"id":"2524294821","title":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524294821","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524294821?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:05","pubTimestamp":1743537900,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., April 01, 2025  -- Revolution Medicines, Inc. , a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research  Annual Meeting in Chicago, held from April 25 – 30, 2025.The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS G12D-selective inhibitor, will be featured in a late breaking oral presentation.Preliminary safety and antitumor activity of zoldonrasib , an oral, RAS G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer  from a Phase 1 study in advanced solid tumors. Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center. Discovery of RMC-5127, an oral, RAS G12V-selective, noncovalent, tri-complex inhibitor. Early reduction in circulating tumor DNA  is associated with clinical activity of daraxonrasib  in RAS mutan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revolution-medicines-deliver-multiple-presentations-200500656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4512","LU2357305700.SGD","BK4588","LU1861215975.USD","LU1861214812.USD","LU1720051108.HKD","BK4141","LU1978683503.SGD","LU2298322129.HKD","LU1861219969.SGD","LU1854103824.USD","LU0124384867.USD","RVMD","BK4585","BK4117","ON","LU0348723411.USD","MDCO","RVMDW","BK4605","LU2360107325.USD","LU1854104046.USD","BK4139","LU0724618433.USD","IE00BD6J9T35.USD","AFG","BK4107","IE00BZ199S13.USD","LU1861220033.SGD","LU1720051017.SGD","LU1548497426.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":153,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCO\",params:#limit:5,,,undefined,":[{"date":"2019-10-30","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"defaultRemindTime":1572422400000,"name":null,"time":"Pre-Market","dateTimestamp":1572408000000,"actualEps":null},{"date":"2019-07-24","symbol":"MDCO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.66,"defaultRemindTime":1563955200000,"name":null,"time":"Pre-Market","dateTimestamp":1563940800000,"actualEps":-0.67},{"market":"US","date":"2019-04-25","symbol":"MDCO","fiscalQuarterEnding":"2019/03","expectedEps":-0.71,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1556164800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2019-02-27","symbol":"MDCO","fiscalQuarterEnding":"2018/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551243600000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2018-11-08","symbol":"MDCO","fiscalQuarterEnding":"2018/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCO\",market:\"US\",delay:false,,,undefined,":{}}}